GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:EGTX) » Definitions » Cyclically Adjusted Revenue per Share

Egetis Therapeutics AB (OSTO:EGTX) Cyclically Adjusted Revenue per Share : kr0.65 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Egetis Therapeutics AB Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Egetis Therapeutics AB's adjusted revenue per share for the three months ended in Mar. 2024 was kr0.041. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.65 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Egetis Therapeutics AB's average Cyclically Adjusted Revenue Growth Rate was -5.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Egetis Therapeutics AB was -3.70% per year. The lowest was -3.70% per year. And the median was -3.70% per year.

As of today (2024-05-19), Egetis Therapeutics AB's current stock price is kr7.00. Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr0.65. Egetis Therapeutics AB's Cyclically Adjusted PS Ratio of today is 10.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Egetis Therapeutics AB was 27.37. The lowest was 4.30. And the median was 7.53.


Egetis Therapeutics AB Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Cyclically Adjusted Revenue per Share Chart

Egetis Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.74 0.75 0.71 0.66

Egetis Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.68 0.66 0.66 0.65

Competitive Comparison of Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted PS Ratio falls into.



Egetis Therapeutics AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Egetis Therapeutics AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.041/132.2054*132.2054
=0.041

Current CPI (Mar. 2024) = 132.2054.

Egetis Therapeutics AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.432 0.000
201409 0.000 100.161 0.000
201412 0.000 100.225 0.000
201503 0.000 99.950 0.000
201506 0.000 99.995 0.000
201509 0.000 100.228 0.000
201512 0.000 100.276 0.000
201603 0.000 100.751 0.000
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.003 102.752 0.004
201709 0.000 103.279 0.000
201712 0.252 103.793 0.321
201803 0.014 103.962 0.018
201806 0.180 104.875 0.227
201809 0.125 105.679 0.156
201812 0.206 105.912 0.257
201903 1.020 105.886 1.274
201906 0.079 106.742 0.098
201909 0.104 107.214 0.128
201912 0.359 107.766 0.440
202003 0.201 106.563 0.249
202006 0.368 107.498 0.453
202009 0.044 107.635 0.054
202012 0.027 108.296 0.033
202103 0.021 108.360 0.026
202106 0.139 108.928 0.169
202109 0.034 110.338 0.041
202112 0.018 112.486 0.021
202203 0.039 114.825 0.045
202206 0.024 118.384 0.027
202209 0.024 122.296 0.026
202212 0.034 126.365 0.036
202303 0.028 127.042 0.029
202306 0.023 129.407 0.023
202309 0.049 130.224 0.050
202312 0.112 131.912 0.112
202403 0.041 132.205 0.041

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Egetis Therapeutics AB  (OSTO:EGTX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Egetis Therapeutics AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.00/0.65
=10.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Egetis Therapeutics AB was 27.37. The lowest was 4.30. And the median was 7.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Egetis Therapeutics AB Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB (OSTO:EGTX) Business Description

Industry
Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB (OSTO:EGTX) Headlines

No Headlines